• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regentis Biomaterials Ltd. Ordinary Shares (NY:RGNT)

2.090 -0.070 (-3.24%)
Official Closing Price Updated: 8:00 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,969
Open 2.100
Bid (Size) 1.960 (100)
Ask (Size) 2.210 (100)
Prev. Close 2.160
Today's Range 2.000 - 2.140
52wk Range 1.232 - 15.50
Shares Outstanding 24,114,610
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Marks Key IP Milestone for GelrinC Manufacturing
August 18, 2026
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial Case for GelrinC in Multi-Billion Knee Cartilage Repair Market
August 14, 2026
Via Investor Brand Network

Performance

YTD
-69.3%
-69.3%
1 Month
+1.5%
+1.5%
3 Month
-3.2%
-3.2%
6 Month
-43.5%
-43.5%
1 Year
-72.1%
-72.1%

More News

Read More
Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks
August 14, 2026
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market
August 13, 2026
Via Investor Brand Network
Topics Intellectual Property
NetworkNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
August 07, 2026
Via Investor Brand Network
Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair
August 05, 2026
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair
July 31, 2026
Via Investor Brand Network
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets $3 Billion Cartilage Repair Market with Cell-Free Gelrin C
July 29, 2026
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Clinical and Regulatory Milestones
July 28, 2026
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market
July 24, 2026
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives Japan Patent Allowance for GelrinC Manufacturing Technology
July 20, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
July 20, 2026
From Regentis Biomaterials Ltd
Via ACCESS Newswire
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process
July 15, 2026
Via Investor Brand Network
News headline image
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
July 15, 2026
From Regentis Biomaterials Ltd
Via ACCESS Newswire
The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics
July 07, 2026
Via Investor Brand Network
News headline image
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
June 17, 2026
From Regentis Biomaterials Ltd
Via ACCESS Newswire
Top movers analysis in the middle of the day on 2026-06-16: top gainers and losers in today's session. ↗
June 16, 2026
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
June 16, 2026
Via Chartmill
These stocks are moving in today's after hours session ↗
June 15, 2026
Via Chartmill
Discover the most active stocks in Monday's session. ↗
June 15, 2026
Via Chartmill
Unusual volume stocks are being observed in Monday's session. ↗
June 15, 2026
Via Chartmill
Here are the top movers in Wednesday's session. ↗
June 10, 2026
Via Chartmill
News headline image
Sphere 3D Corp. (NASDAQ: ANY): Why Its 53MW Power Platform Is Drawing Attention Beyond Bitcoin Mining
June 10, 2026
Via AB Newswire
Topics Artificial Intelligence Economy
Top stock movements in today's session. ↗
June 10, 2026
Via Chartmill
Wednesday's session: gap up and gap down stocks ↗
June 10, 2026
Via Chartmill

Frequently Asked Questions

Is Regentis Biomaterials Ltd. Ordinary Shares publicly traded?
Yes, Regentis Biomaterials Ltd. Ordinary Shares is publicly traded.
What exchange does Regentis Biomaterials Ltd. Ordinary Shares trade on?
Regentis Biomaterials Ltd. Ordinary Shares trades on the New York Stock Exchange
What is the ticker symbol for Regentis Biomaterials Ltd. Ordinary Shares?
The ticker symbol for Regentis Biomaterials Ltd. Ordinary Shares is RGNT on the New York Stock Exchange
What is the current price of Regentis Biomaterials Ltd. Ordinary Shares?
The current price of Regentis Biomaterials Ltd. Ordinary Shares is 2.090
When was Regentis Biomaterials Ltd. Ordinary Shares last traded?
The last trade of Regentis Biomaterials Ltd. Ordinary Shares was at 08/25/26 08:00 PM ET
What is the market capitalization of Regentis Biomaterials Ltd. Ordinary Shares?
The market capitalization of Regentis Biomaterials Ltd. Ordinary Shares is 50.40M
How many shares of Regentis Biomaterials Ltd. Ordinary Shares are outstanding?
Regentis Biomaterials Ltd. Ordinary Shares has 50M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap